Mimrylo™ rusfertide for injection

Leveraging Oracle® Health EHR Capabilities

to Support the Treatment of Patients With Polycythemia Vera (PV)

EHR=electronic health record.

INDICATION

MIMRYLO is indicated for the treatment of erythrocytosis in adults with polycythemia vera (PV).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **New or Worsening Thrombocytosis:** MIMRYLO may increase platelet counts in patients with PV. Platelet counts generally plateaued on treatment by Week 8. After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated. Platelet elevations associated with MIMRYLO may require cytoreductive therapy initiation, modification, or MIMRYLO dose modifications or discontinuation.
- **Injection-Site Reactions:** Injection site reactions (including Grade 3 reactions) have been reported in patients treated with MIMRYLO. The most common injection site reactions reported were erythema, pruritus, pain, and swelling. Use ice, topical corticosteroid creams, antihistamines or analgesics, as needed, to treat injection site pain and swelling.
- **Embryo-Fetal Toxicity:** Based on findings from animal reproduction studies, MIMRYLO may cause fetal harm when administered to a pregnant woman. Advise patients to stop taking MIMRYLO if they become pregnant.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Takeda

About This Guide

This instructional guide provides information to assist with updating the EHR to support MIMRYLO™ (rusfertide), a treatment option for patients with PV. It includes examples and steps to inform healthcare providers on including MIMRYLO in prescribing workflow capabilities.

The information listed in this resource is based upon the most recent version of Oracle® Health; functions and features may change as new software versions are released. This resource is meant to serve as summary information only and should not replace detailed instructions provided to you by your internal or external EHR support resources. Screen images shown within represent hypothetical screens in Oracle Health. Takeda makes no claims or warranties about the applicability or appropriateness of this information.

This guide is meant to provide guidance for you, your office manager, your EHR champion, and information technology (IT) staff about MIMRYLO. It provides examples for discussion purposes only, does not constitute guidance or medical advice for treatment, and does not represent all workflows for implementation. It is ultimately the responsibility of the healthcare provider to select a treatment based on their independent medical judgment and the need of each individual patient and to determine and implement the appropriate workflows.

The instructions listed in this guide are for use with the most current version of Oracle Health systems. Although the instructions have been tested on this EHR system, they are not guaranteed to work for all available software versions. These materials have not been reviewed or endorsed by Oracle Health.

The user is solely responsible for the implementation, testing, and monitoring to ensure proper orientation in the EHR system.

IMPORTANT SAFETY INFORMATION (cont.)

ADVERSE REACTIONS

The most common (>15%) adverse reactions were injection site reactions (56%) and anemia (16%).

USE IN SPECIFIC POPULATIONS

- **Lactation:** Because of the potential for serious adverse reactions in the breastfed child, including impaired iron absorption, advise patients not to breastfeed during treatment with MIMRYLO and for 30 days after the final treatment.
- **Females and Males of Reproductive Potential**
  - **Pregnancy Testing:** Prior to initiating MIMRYLO, pregnancy testing is recommended for females of reproductive potential.
  - **Contraception:** Advise female patients of reproductive potential to use effective contraception during treatment with MIMRYLO and for at least 30 days after the final dose of MIMRYLO.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

About This Guide (cont.)

Table of Contents

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **New or Worsening Thrombocytosis:** MIMRYLO may increase platelet counts in patients with PV. Platelet counts generally plateaued on treatment by Week 8. After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated. Platelet elevations associated with MIMRYLO may require cytoreductive therapy initiation, modification, or MIMRYLO dose modifications or discontinuation.
- **Injection-Site Reactions:** Injection site reactions (including Grade 3 reactions) have been reported in patients treated with MIMRYLO. The most common injection site reactions reported were erythema, pruritus, pain, and swelling. Use ice, topical corticosteroid creams, antihistamines or analgesics, as needed, to treat injection site pain and swelling.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

Why This Matters

PV is a chronic myeloproliferative neoplasm (MPN) characterized by red blood cell overproduction that can lead to far reaching outcomes due to uncontrolled hematocrit (HCT), persistent symptom burden, and iron dysregulation.[1-7]

In a real-world study, 78% of patients were not able to consistently control HCT below 45% despite being on treatment.[2,3] In fact, only 14% of low-risk and 25% of high-risk patients consistently maintained HCT below 45% despite treatment with phlebotomy with or without cytoreductive therapy.[2]*

When HCT is even slightly elevated (45%-50%), people are 4x more likely to experience major thrombolytic events or CV death vs when HCT is <45%.[8]†

For many patients, increased symptom burden is more than discomfort; it can reduce overall survival in people with PV.[‡§4] In a retrospective study, approximately 60% of patients showed laboratory evidence of iron depletion (N=38).[6] Iron deficiency may persist or worsen with ongoing therapeutic phlebotomy, especially as erythrocytosis continues, and can lead to:[12-15]

- Fatigue
- Brain fog
- Physical inactivity
- Weakness and dizziness

The primary aim of PV management is to maintain HCT below the 45% threshold. Other treatment goals include:[8,10-11]

- Reducing the burden of phlebotomy
- Symptom reduction
- Delaying disease progression

Current PV treatment guidelines are focused on keeping HCT below the 45% threshold and monitoring disease progression but may not capture fluctuating HCT and associated risks.[5,10]

*Based on a retrospective, observational real-world study of 28,306 patients with PV initiating treatment in the US between 2011 and 2019. Real-world analyses often have limitations and include the potential for incomplete or missing records and misdiagnosis of PV, as diagnoses were based solely on database records. There is the possibility that thrombotic events were misdiagnosed, underdiagnosed, or otherwise, incorrectly reported. Outcomes and comparisons between studies should be interpreted with caution.[1]

†In an Italian RCT study (CYTO-PV) of 365 PV patients being treated with phlebotomy, hydroxyurea, or both, 2.7% (n=5/182) with HCT <45% died from CV causes or had major thrombotic events vs 9.8% (n=18/183) with HCT 45%-50%, after a median follow-up of 31 months (HR, 3.91; 95% CI, 1.45-10.53; P=0.007).[3]

‡Based on an analysis of PV patients with high symptom burden (defined as Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score [MPN-SAF TSS] >35) [n=24] vs those with low symptom (P=0.002) burden (n=256).[9]

§A multicenter, retrospective, observational study comprising patients from 13 academic and community centers. Eligibility criteria were patients >18 years old, enrolled with a diagnosis of PV, ET or MF (primary or post-PV/ET) according to WHO and/or International Consensus criteria, and having completed at least one MPN-SAF TSS questionnaire between April 2013 and August 2022.[4]

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

- **Embryo-Fetal Toxicity:** Based on findings from animal reproduction studies, MIMRYLO may cause fetal harm when administered to a pregnant woman. Advise patients to stop taking MIMRYLO if they become pregnant.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

Why This Matters (cont.)

Optimizing Workflow to Facilitate the Prescribing of MIMRYLO™ (rusfertide)

Updating EHR workflow can help address the potential for confusion around MIMRYLO dosing that can ultimately lead to delays.

MIMRYLO is initiated using a standardized starting approach. Based on individual patient response and tolerability, modification may be considered to support achievement or maintenance of the desired therapeutic effect (e.g., HCT <45%). Dose reduction may also be appropriate if clinically significant anemia or other treatment-related adverse events should occur.

When considering a dose adjustment, note that single-dose vials are available in 5 different strengths: 9.5 mg, 19 mg, 28 mg, 41 mg, and 54 mg. Therefore, some prescribed doses may require a combination of these vial strengths (e.g., 28 mg + 41 mg to achieve 69 mg) or increasing the quantity (e.g., 82 mg would require two 41 mg vials). In cases where different vial strengths are combined, 2 separate prescriptions will need to be written since the pharmacy will need to dispense 2 distinct kits. This guide includes instructions for creating an orderable item for doses requiring 2 separate strengths and therefore 2 separate prescriptions.

Dosing Overview: Matching Prescriptions to Intended Dose

Weekly Dose	Sample Sig	Number of Prescriptions Required
9.5 mg	Inject one 9.5 mg kit	1
19 mg	Inject one 19 mg kit	1
28 mg	Inject one 28 mg kit	1
41 mg	Inject one 41 mg kit	1
54 mg	Inject one 54 mg kit	1
69 mg	Inject one 28 mg kit and one 41 mg kit weekly	2 1x28 mg kit per week and 1x41 mg kit per week
82 mg	Inject two 41 mg kits weekly	1 2x41 mg kits per week
95 mg	Inject one 54 mg kit and one 41 mg kit weekly	2 1x54 mg kit per week and 1x41 mg kit per week
108 mg	Inject two 54 mg kits weekly	1 2x54 mg kits per week

IMPORTANT SAFETY INFORMATION (cont.)

ADVERSE REACTIONS

The most common (>15%) adverse reactions were injection site reactions (56%) and anemia (16%).

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

Why This Matters (cont.)

EHR Tools to Address Dosing

This guide focuses on several EHR tools that can be beneficial to help ensure that the proper dose of MIMRYLO™ (rusfertide) is prescribed and adhered to, including:

- PowerPlans
- Discern Rules
- Discern Analytics
- Dynamic Worklists
- Discern Alerts
- Patient education orders

IMPORTANT SAFETY INFORMATION (cont.)

USE IN SPECIFIC POPULATIONS

- **Lactation:** Because of the potential for serious adverse reactions in the breastfed child, including impaired iron absorption, advise patients not to breastfeed during treatment with MIMRYLO and for 30 days after the final treatment.
- **Females and Males of Reproductive Potential**
  - **Pregnancy Testing:** Prior to initiating MIMRYLO, pregnancy testing is recommended for females of reproductive potential.
  - **Contraception:** Advise female patients of reproductive potential to use effective contraception during treatment with MIMRYLO and for at least 30 days after the final dose of MIMRYLO.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

MIMRYLO™ (rusfertide) PowerPlans

In Oracle® Health, a prescription PowerPlan provides a standardized, evidence-based order set that bundles medications directly into the patient's broader care pathway. Rather than standalone, ad-hoc entries, PowerPlans may help ensure accurate dosing while reducing the burden on healthcare providers.

This guide uses a subphase-based PowerPlan design to support a more modular, reusable, and maintainable build approach within Oracle Health. Rather than embedding all orders directly within a single, self-contained PowerPlan, this method leverages standalone subphases that can be selectively added to new or existing PowerPlans as needed.

Creating a New PowerPlan

1. Launch the **PowerPlan Tool.**
2. Select the **Copy Plan** icon.
3. Name the new PowerPlan; for example, MIMRYLO Prescriptions.
4. Navigate to the copied plan.
5. Generate header-style notes to account for the different MIMRYLO doses.
    a. Select the **Note** tab, insert the appropriate text, and select **Add**
    b. Repeat this step until all necessary notes are added, per the Dosing Overview
6. Add specific MIMRYLO orders under their respective headers.
    a. Select the **order** tab, search for MIMRYLO, select all the MIMRYLO orders, pull them into the current list, and select **Add**



Example of adding doses to header sections

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **New or Worsening Thrombocytosis:** MIMRYLO may increase platelet counts in patients with PV. Platelet counts generally plateaued on treatment by Week 8. After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated. Platelet elevations associated with MIMRYLO may require cytoreductive therapy initiation, modification, or MIMRYLO dose modifications or discontinuation.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

MIMRYLO™ (rusfertide) PowerPlans (cont.)

7. Drag and drop respective doses into their section headers.
8. Select the first MIMRYLO **Order**, navigate to the Order Sentence/Expectation Attribute. Right-click and select **Add**.



Example of adding doses to header sections



Example of adding MIMRYLO to Order Sentence/Expectation Attribute

9. Complete all applicable order details.



Example of order details for the MIMRYLO order sentence

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

- **Injection-Site Reactions:** Injection site reactions (including Grade 3 reactions) have been reported in patients treated with MIMRYLO. The most common injection site reactions reported were erythema, pruritus, pain, and swelling. Use ice, topical corticosteroid creams, antihistamines or analgesics, as needed, to treat injection site pain and swelling.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

MIMRYLO™ (rusfertide) PowerPlans (cont.)

10. Repeat steps 8 and 9 until all order sentences are complete.
11. It is necessary to create **Build Link Components Group** for doses requiring multiple strengths.
    a. Select the **PowerPlan** level. Under the **Attribute Name**, find **Build Linked Components Group** and select **Click here to add**
    b. Select **Add New Group** and name it according to the selected dose



Example of where to locate and select build linked components group attribute



Example of naming a group name

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

- **Embryo-Fetal Toxicity:** Based on findings from animal reproduction studies, MIMRYLO may cause fetal harm when administered to a pregnant woman. Advise patients to stop taking MIMRYLO if they become pregnant.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

MIMRYLO™ (rusfertide) PowerPlans (cont.)

c. Set the **Rule Type** to **Exactly** and the **Rule Quantity** to **2**. Then pull over the first pairing for the 69 mg and select **Apply**

d. Pull over the second pairing for the 69 mg dose and select **Apply**, then select **OK**

e. Repeat step 12 for all necessary pairings for a total of 4 Build Linked Component Groups. For each grouping built, chain links will be visible



Example of Build Linked Component Groups with chain links for groupings



Example of adding required prescriptions for the MIMRYLO 69 mg dose

12. Save the Subphase and cycle the following Servers:

a. Cycle -entry 51
b. Cycle -entry 115
c. Cycle -entry 119
d. Cycle -entry 362
e. Cycle -entry 378
f. Cycle -entry 506

IMPORTANT SAFETY INFORMATION (cont.)

ADVERSE REACTIONS

The most common (>15%) adverse reactions were injection site reactions (56%) and anemia (16%).

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

MIMRYLO™ (rusfertide) PowerPlans (cont.)



Example of completed order subphase

IMPORTANT SAFETY INFORMATION (cont.)

USE IN SPECIFIC POPULATIONS

- **Lactation:** Because of the potential for serious adverse reactions in the breastfed child, including impaired iron absorption, advise patients not to breastfeed during treatment with MIMRYLO and for 30 days after the final treatment.
- **Females and Males of Reproductive Potential**
  - **Pregnancy Testing:** Prior to initiating MIMRYLO, pregnancy testing is recommended for females of reproductive potential.
  - **Contraception:** Advise female patients of reproductive potential to use effective contraception during treatment with MIMRYLO and for at least 30 days after the final dose of MIMRYLO.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

MIMRYLO™ (rusfertide) PowerPlans (cont.)

Adding a Subphase to an Existing PowerPlan

1. Launch the **PowerPlan Tool** and search for the applicable PowerPlan your organization uses for these types of orders. Select the PowerPlan and select **OK**.
2. Select **Add/Modify Subphase**.
3. Add a MIMRYLO Prescriptions Phase.
4. Select the newly created MIMRYLO Prescriptions Phase, then select the **Subphase** tab.
5. Search for and select the MIMRYLO subphase, then select **Add**.



Example of completed order subphase

6. This subphase now appears in the PowerPlan and can be set as included by default for ordering.
7. Select **Save Plan** and cycle the following Servers:
   a. Cycle -entry 51
   b. Cycle -entry 115
   c. Cycle -entry 119
   d. Cycle -entry 362
   e. Cycle -entry 378
   f. Cycle -entry 506

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **New or Worsening Thrombocytosis:** MIMRYLO may increase platelet counts in patients with PV. Platelet counts generally plateaued on treatment by Week 8. After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated. Platelet elevations associated with MIMRYLO may require cytoreductive therapy initiation, modification, or MIMRYLO dose modifications or discontinuation.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Discern Rule

Creating a Discern Rule to Support Ordering MIMRYLO™ (rusfertide) From Specialty Pharmacies

The steps in this section describe how to configure a Discern Rule to support ordering a medication that is fulfilled through Takeda Oncology Here2Assist.

In this workflow, the medication itself is ordered through the MIMRYLO PowerPlan. The Discern Rule logic described below does not replace the medication order or alter the clinical intent of the order.

Instead, it provides context-aware support once the order is placed, helping guide users through operational steps associated with specialty pharmacy fulfillment.

These Discern Rules are designed to:

- Recognize when the medication has been ordered
- Confirm that the order meets criteria for specialty pharmacy handling
- Present guidance, alerts, or next-step instructions aligned with the two selected specialty pharmacies

Creating the Discern Rule

1. Launch **dcptools.exe**.
2. Navigate to **Order Management** and the **Order Entry Format Tool**.
3. Select **Formats**.
4. Select **Add**, type in a format name; for example, **Communication Order – Takeda Oncology Here2Assist**. Choose a catalog type; for example, **Patient Care**. Check the **Copy another format** box and select the format you want to copy per health system standards. Select **OK**.
5. Select the newly copied **Format**.
6. Relabel fields to Required according to health system standards; for example:
    a. **Requested start date and time**: Required
    b. **Instructions for Takeda Oncology Here2Assist**: Required
    c. **Provider Contact**: Required

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

- **Injection-Site Reactions:** Injection site reactions (including Grade 3 reactions) have been reported in patients treated with MIMRYLO. The most common injection site reactions reported were erythema, pruritus, pain, and swelling. Use ice, topical corticosteroid creams, antihistamines or analgesics, as needed, to treat injection site pain and swelling.

Discern Rule (cont.)



Example of relabeling fields to indicate what will be required

7. Close the **Format** tool and open the **Order Catalog Entry** tool.
8. Select **Copy From**.



Example of selecting Copy From in the Order Catalog Entry tool

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

- **Embryo-Fetal Toxicity:** Based on findings from animal reproduction studies, MIMRYLO may cause fetal harm when administered to a pregnant woman. Advise patients to stop taking MIMRYLO if they become pregnant.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

Discern Rule (cont.)

9. Search for a like-orderable; for example, an existing Communication Order for a medication orderable and select **OK**.
10. Name the new Order according to health system standards; for example, Discern Rule Orderable Name.
11. Select the Communication Order – specialty pharmacy hub **Order Format** and select **Apply**.



Example of selecting the Communication Order–Takeda Oncology Here2Assist Order Format

Adding the Communication Order

1. Launch **dcptools.exe**.
2. Navigate to **Order Management** and select **PowerPlan Tool**.
3. Select **Plan Selection** and search for MIMRYLO™ (rusfertide).
4. Select the **Note** tab and type in a guiding note about entering the correct information to be sent to Takeda Oncology Here2Assist; for example, MIMRYLO orders should be routed through Takeda Oncology Here2Assist.

IMPORTANT SAFETY INFORMATION (cont.)

ADVERSE REACTIONS

The most common (>15%) adverse reactions were injection site reactions (56%) and anemia (16%).

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

Discern Rule (cont.)

5. Select the **Order** tab, search for Takeda Oncology Here2Assist for MIMRYLO**,** and include it in the subphase.



Example of adding discern rule orderable name to the order

6. Drag and drop both the Note and the Takeda Oncology Here2Assist for MIMRYLO to the top of the MIMRYLO Subphase.



Example of adding the note and Takeda Oncology Here2Assist for MIMRYLO to the top of the subphase

IMPORTANT SAFETY INFORMATION (cont.)

USE IN SPECIFIC POPULATIONS

- **Lactation:** Because of the potential for serious adverse reactions in the breastfed child, including impaired iron absorption, advise patients not to breastfeed during treatment with MIMRYLO and for 30 days after the final treatment.
- **Females and Males of Reproductive Potential**
  - **Pregnancy Testing:** Prior to initiating MIMRYLO, pregnancy testing is recommended for females of reproductive potential.
  - **Contraception:** Advise female patients of reproductive potential to use effective contraception during treatment with MIMRYLO and for at least 30 days after the final dose of MIMRYLO.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Discern Rule (cont.)

7. Select the Takeda Oncology Here2Assist for MIMRYLO™ (rusfertide) and select defaults **Include** and **Require**.



Example of making the specialty pharmacy information a default and included in orders

8. Select **Save Plan**.

Configuring EKM Rule

1. Launch **DiscernDev**.
   a. Create a new rule according to health system standards.
2. Fill in parameters according to health system rule parameters; for example:
   a. Description of the module
   b. Duration of the module
   c. File name
   d. Author
3. Select the **Knowledge** tab and choose **Select Evoke Event**.
4. Search for **Order**, select **Order Event**, and select **OK**.
5. Right-click the **Evoke Section** and select **Insert Template**.
6. Select **EKS_ORDER_LIST_E**, then select **Finish**.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **New or Worsening Thrombocytosis:** MIMRYLO may increase platelet counts in patients with PV. Platelet counts generally plateaued on treatment by Week 8. After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated. Platelet elevations associated with MIMRYLO may require cytoreductive therapy initiation, modification, or MIMRYLO dose modifications or discontinuation.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Discern Rule (cont.)

7. Set the appropriate parameters.

Evoke on ORDER EVENT **where,**

E1 EKS_ORDER_LIST_E ✔
an order whose primary mnemonic is* Takeda Oncology Here2Assist for MIMRYLO with status of Ordered* and an optional order detail of OPT ORDER DETAIL that OPT QUALIFIER OPT LIST

Example of parameters for EKS_ORDER_LIST_E

8. Right-click in the **Logic** section and select **Insert Template**, search for and select **EKS_LOGIC_TRUE**, then select **Finish**.
9. Right-click in the **Logic** section and select **Insert Template After**. Search for and select **EKS_ORDER_LIST_INCOMING_L**, then select **Finish**. Set the appropriate parameters.

L3 EKS_ORDER_LIST_INCOMING_L ✔
the triggering request contains an order **whose primary mneumonic is*** Takeda Oncology Here2Assist with status of **Ordered** and an optional order detail of OPT ORDER DETAIL that OPT QUALIFIER OPT LIST

Example of parameters for EKS_ORDER_LIST_INCOMING_L

10. Right-click in the **Action** section and select **Insert Template**. Select **EKS_MESSENGER_A** then select **Finish**.
11. Select the **RECIPIENT** parameter and complete it with the appropriate recipient email addresses.
12. Select the **Subject** parameter and add a subject line according to health system standards; for example, @ Patient:1 has a new MIMRYLO™ (rusfertide) prescription.
13. Select the **MSG** parameter and include a message using substitution values.

Example message using substitution values

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

- **Injection-Site Reactions:** Injection site reactions (including Grade 3 reactions) have been reported in patients treated with MIMRYLO. The most common injection site reactions reported were erythema, pruritus, pain, and swelling. Use ice, topical corticosteroid creams, antihistamines or analgesics, as needed, to treat injection site pain and swelling.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

Discern Rule (cont.)

14. Select **File** then select **Save As** and name the rule according to health system standards; for example, **Takeda Oncology Here2Assist for MIMRYLO**. Select **OK**.
15. Cycle the following servers:
    a. Cycle -entry 150
    b. Cycle -entry 151
    c. Cycle -entry 152
    d. Cycle -entry 153
    e. Cycle -entry 175
    f. Cycle -entry 176

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

- **Embryo-Fetal Toxicity:** Based on findings from animal reproduction studies, MIMRYLO may cause fetal harm when administered to a pregnant woman. Advise patients to stop taking MIMRYLO if they become pregnant.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

Discern Analytics

Discern Analytics is a data retrieval and visualization tool that enables users to query clinical, financial, and operational data. Discern Analytics can be used to identify patients with specific conditions, measure the size of the patient population, assess the impact of current treatment, evaluate gaps in care, and guide targeted patient outreach.

Reports generated using Discern Analytics are based on the organization's own criteria, including diagnosis, lab result values, and medications. These reports may be used for targeted patient outreach and/or healthcare provider (HCP) messaging. Patient reports can also be used to monitor patient outcomes and adherence to treatment regimens.

Configuring Discern Analytics

1. Launch **Discern Analytics** (DA2.exe).
2. Select the **Navigator** tab, access the **Domains** tab, and select the appropriate domain to query.



Example of selecting the Discern Sample Domain Folder

IMPORTANT SAFETY INFORMATION (cont.)

ADVERSE REACTIONS

The most common (>15%) adverse reactions were injection site reactions (56%) and anemia (16%).

USE IN SPECIFIC POPULATIONS

- **Lactation:** Because of the potential for serious adverse reactions in the breastfed child, including impaired iron absorption, advise patients not to breastfeed during treatment with MIMRYLO and for 30 days after the final treatment.
- **Females and Males of Reproductive Potential**
  - **Pregnancy Testing:** Prior to initiating MIMRYLO, pregnancy testing is recommended for females of reproductive potential.
  - **Contraception:** Advise female patients of reproductive potential to use effective contraception during treatment with MIMRYLO and for at least 30 days after the final dose of MIMRYLO.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Discern Analytics (cont.)

3. Right-click the selected domain and choose **New Query**.
4. Select the **Query List** tab, highlight **Query1**, and select **Rename**.
5. Name the query according to health system naming conventions; for example, Patients_MIMRYLO.



Example of selecting Domain and New Query



Example of selecting Domain and New Query

6. Select the **Patients_MIMRYLO** Query tab.

Example of selecting the new query tab

7. Follow the following folder path: **Person** > **Demographics** > **Name—Full**. Add **Name—Full** to the **Selected Columns** section and **Qualifications** section.



Example of selecting Name-Full and adding it to Selected Columns and Qualifications

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **New or Worsening Thrombocytosis:** MIMRYLO may increase platelet counts in patients with PV. Platelet counts generally plateaued on treatment by Week 8. After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated. Platelet elevations associated with MIMRYLO may require cytoreductive therapy initiation, modification, or MIMRYLO dose modifications or discontinuation.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

Discern Analytics (cont.)

8. Search for **Diagnosis** and add it to **Selected Columns** and **Qualifications**.
9. Search for **Order** and add **Order Long Description** to **Selected Columns** and **Qualifications**.
10. Search for **Clinical** and add **Clinical Event** and **Clinical Event Result Unit** to **Selected Columns** and **Qualifications**.



Example of adding domains, clinical concept and observation, diagnosis, and clinical metadata to selected columns and qualifications

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

- **Injection-Site Reactions:** Injection site reactions (including Grade 3 reactions) have been reported in patients treated with MIMRYLO. The most common injection site reactions reported were erythema, pruritus, pain, and swelling. Use ice, topical corticosteroid creams, antihistamines or analgesics, as needed, to treat injection site pain and swelling.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

Discern Analytics (cont.)

11. To add qualifiers for the report, begin by selecting **Modify Filter List** under **Diagnosis Code**. Search for and move D45 to the right. Select **Include**.



Example of adding diagnosis code as a report qualifier

12. **Select Modify Filter List** under the **Order Long Description Qualifier**. Search for and select MIMRYLO™ (rusfertide), move it to the right, and select **Include**.



Example of adding MIMRYLO to the Report Qualifier

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

- **Embryo-Fetal Toxicity:** Based on findings from animal reproduction studies, MIMRYLO may cause fetal harm when administered to a pregnant woman. Advise patients to stop taking MIMRYLO if they become pregnant.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Discern Analytics (cont.)

13. Select **Modify Filter List** under **Clinical Event**. Search for and select HCT. Move it to the right and select Include.
14. Select **Modify Filter List** under **Clinical Event Result Unit**. Search for and select %. Move it to the right and select **Include**.
15. Select **Filtered List** in the top right of the **Qualifications** section and change it to **Constant**, set to >=45.



Example of adding HCT as >=45 as a Constant for report criteria

16. Select **Save Query As** and name it according to health system naming conventions; for example, Patients_MIMRYLO.
17. Run the **Query Preview**.
18. Enter the **max row value** and **max timeout value** according to health system standards. Select **OK**.



Example of DA2 query preview

IMPORTANT SAFETY INFORMATION (cont.)

ADVERSE REACTIONS

The most common (>15%) adverse reactions were injection site reactions (56%) and anemia (16%).

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Dynamic Worklist

A Dynamic Worklist is a real-time, filtered list of patients or tasks (e.g., alerts for medications that are due/overdue, cosignature requests, pre-authorization flags) that automatically updates based on specific clinical or operational criteria. Dynamic Worklists help push the most relevant information to clinicians based on where patients currently are in their care.

Creating a Dynamic Worklist

1. Launch **herulebuilder.exe**.
2. Under **Rule Group**, select the dropdown and choose **Conditions**.



Example of selecting Conditions for the Rule Group

3. Select **Edit** then select **New Rule**.
4. Name the New Rule according to health system naming conventions; for example, MIMRYLO™ (rusfertide) Patients and select **OK**.



Example of naming the new Rule

IMPORTANT SAFETY INFORMATION (cont.)

USE IN SPECIFIC POPULATIONS

- **Lactation:** Because of the potential for serious adverse reactions in the breastfed child, including impaired iron absorption, advise patients not to breastfeed during treatment with MIMRYLO and for 30 days after the final treatment.
- **Females and Males of Reproductive Potential**
  - **Pregnancy Testing:** Prior to initiating MIMRYLO, pregnancy testing is recommended for females of reproductive potential.
  - **Contraception:** Advise female patients of reproductive potential to use effective contraception during treatment with MIMRYLO and for at least 30 days after the final dose of MIMRYLO.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Dynamic Worklist (cont.)

5. Select the newly created MIMRYLO™ (rusfertide) Patients Condition from the list and select **Add Sentence**.
6. Select **Diagnosis** and choose the **If** statement "**The person has a diagnosis type <type> with a vocabulary of <vocabulary>; that equals <code>**" and select **Add**.



Example of selecting the If statement

7. Define the **Then** statement by selecting **Condition** and add the **Condition** statement of "**The person has a condition of <condition>**." Select **Add**.



Example of selecting the Then statement

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **New or Worsening Thrombocytosis:** MIMRYLO may increase platelet counts in patients with PV. Platelet counts generally plateaued on treatment by Week 8. After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated. Platelet elevations associated with MIMRYLO may require cytoreductive therapy initiation, modification, or MIMRYLO dose modifications or discontinuation.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Dynamic Worklist (cont.)

8. Select the parameter variable <**type**> and set it to **applicable types** and select **OK**.



Example of selecting applicable parameters

9. Select **<vocabulary>**, set it to the **ICD-10 Vocabularies**, and select **OK**.
10. Select **<code>** and add all applicable ICD-10 codes; for example, **D45.**
11. The If statement should now read:

If At least one of of the following is true
The person has a diagnosis of type Admitting OR Billing Diagnosis OR Discha... with a vocabulary of ICD-10 that equals D45

Example of the final If statement

12. Select **<condition>** and add the name of the condition; for example, **Patients_MIMRYLO**.
13. Select the **Save** button and **Publish** when the report is ready to release to the organization.
14. This new condition can be used as a qualifier for Dynamic Worklist creations.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

- **Injection-Site Reactions:** Injection site reactions (including Grade 3 reactions) have been reported in patients treated with MIMRYLO. The most common injection site reactions reported were erythema, pruritus, pain, and swelling. Use ice, topical corticosteroid creams, antihistamines or analgesics, as needed, to treat injection site pain and swelling.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

Dynamic Worklist (cont.)

Configuring Dynamic Worklist for Patients Prescribed MIMRYLO™ (rusfertide)

1. Launch **PowerChart.exe**.
2. Select **Dynamic Worklist** from the toolbar.
3. Select the **Create Worklist** button.
4. Name the worklist according to health system naming conventions; for example, **Patients_MIMRYLO**.
5. Define if the worklist will be Group/Provider relationship or Location based. For this example, use **Location List**.
   a. If **Group/Provider** is selected, search for a specific provider(s) or select a predefined group(s) and define the appropriate patient relationship
   b. If **Location** is selected, select the location(s) to be considered. This will be drilled down to the unit level and a lookback timeframe will need to be defined
6. Select the **Facility**(s), **Building**(s), and **Unit**(s) for the worklist. Add a lookback range; for example, Past 365, Time Units Days.
7. Select **Next**.
8. Define **Criteria** per category. For this worklist, select **Laboratory**.



Example of selecting criteria for the worklist

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

- **Embryo-Fetal Toxicity:** Based on findings from animal reproduction studies, MIMRYLO may cause fetal harm when administered to a pregnant woman. Advise patients to stop taking MIMRYLO if they become pregnant.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Dynamic Worklist (cont.)

9. Define the Dynamic Worklist criteria category criteria:
    a. **Select**: Or
    b. **Name**: HCT
    c. **Quantity**: At Least1
    d. **Value**: Greater than or equal 45
    e. **Lookback Range**: 546 Days
10. Select **Conditions** then select **Or** and the diagnosis for the ICD-10 used; for example, D45.
11. Select **Medications** then select **Or**. Select **Name** and search for MIMRYLO™ (rusfertide) and select **Next**.



Example of searching for and adding MIMRYLO as a medication criteria in the worklist

12. Select **Finish**. The Dynamic Worklist will load and be available to export based on selected Categories and Criteria.
13. Select **List Actions** and then **Export Worklist**. Save the worklist in the desired location.

IMPORTANT SAFETY INFORMATION (cont.)

ADVERSE REACTIONS

The most common (>15%) adverse reactions were injection site reactions (56%) and anemia (16%).

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Discern Alert

Discern Alerts are notifications within the EHR that prompt consideration of clinical actions, such as ordering tests, evaluating treatment, sending a referral, or scheduling follow-up care. Discern Alerts are triggered by specific data logic that is configurable and customizable by the health system.

Creating a Discern Alert

1. Launch **DiscernDev**.
2. Create a new rule according to health system standards.
3. Fill in **parameters** according to health system rule parameters; for example:
   a. Description of the module
   b. Duration of the module
   c. File Name
   d. Author
4. Select the **Knowledge** tab and choose **Select Evoke Event**.
5. Search for and select **OPENCHART** and then select **OK**.
6. Right-click in the **Evoke Section** and select **Insert Template**.
7. Select **EKS_USER_POSITION_E** then select **Finish**.
8. Set the first parameter to **is listed in**.

Example of setting the first parameter

9. Select the **POSITION** parameter and search for the positions who should see this alert; for example, Physician and Advanced Practice Provider. Select **Finish**.
10. Right-click in the **Logic** section and select **Insert Template**.

IMPORTANT SAFETY INFORMATION (cont.)

USE IN SPECIFIC POPULATIONS

- **Lactation:** Because of the potential for serious adverse reactions in the breastfed child, including impaired iron absorption, advise patients not to breastfeed during treatment with MIMRYLO and for 30 days after the final treatment.
- **Females and Males of Reproductive Potential**
  - **Pregnancy Testing:** Prior to initiating MIMRYLO, pregnancy testing is recommended for females of reproductive potential.
  - **Contraception:** Advise female patients of reproductive potential to use effective contraception during treatment with MIMRYLO and for at least 30 days after the final dose of MIMRYLO.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Discern Alert (cont.)

11. Search for and select **EKS_LOGIC_TRUE** then select **Finish**.



Example of selecting EKS_LOGIC_TRUE logic

12. Right-click in the **Logic** section and select **Insert Template After**.
13. Search for and select **EKS_DIAGNOSIS_FIND_L** then select **Finish**.
14. Set the parameters according to the desired criteria that includes the ICD-10 code; for example, D45.



Example of setting parameters for the Logic template

15. Right-click in the **Logic** section and choose **Insert Template After**.
16. Search for and select **EKS_CE_RESULT_MOST_RECENT_L** then select **Finish**.
17. Search for and select **EKS_CE_RESULT_CHILD_L** then select **Finish**.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **New or Worsening Thrombocytosis:** MIMRYLO may increase platelet counts in patients with PV. Platelet counts generally plateaued on treatment by Week 8. After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated. Platelet elevations associated with MIMRYLO may require cytoreductive therapy initiation, modification, or MIMRYLO dose modifications or discontinuation.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

Discern Alert (cont.)

18. Set the parameters for this Logic template to include HCT greater than or equal to 45.

Example of setting the parameters for the Logic template

19. Right-click in the **Logic** section and choose **Insert Template After**; search for **EKS_ORDER_MED_INCOMING_L** then select **Finish**.
20. Set the **ORD_METHOD** as **that was ordered as**.
21. Select the **OPT_ORDERS** parameter. Search for and select MIMRYLO™ (rusfertide).



Example of searching for and adding MIMRYLO to the logic

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

- **Injection-Site Reactions:** Injection site reactions (including Grade 3 reactions) have been reported in patients treated with MIMRYLO. The most common injection site reactions reported were erythema, pruritus, pain, and swelling. Use ice, topical corticosteroid creams, antihistamines or analgesics, as needed, to treat injection site pain and swelling.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Discern Alert (cont.)

22. Right-click in the **Action** section and select **Insert Template**.
23. Select **EKS_ALERT_FLEX_A** then select **Finish**.
24. Set the OPT_TITLE as Patients prescribed MIMRYLO™ (rusfertide).

Example of naming the alert

25. Enter the appropriate **TXT** parameters; for example, Patient has a recent Hct ≥45% and is on MIMRYLO. Review clinical data for potential dose adjustment.

Example of adding TXT

26. Add any additional applicable parameters.
27. Select **File**, then select **Save As** and name the rule according to health system standards; for example, **MIMRYLO_HCT_Results**.
28. Cycle the following Servers:
    a. Cycle -entry 150
    b. Cycle -entry 151
    c. Cycle -entry 152
    d. Cycle -entry 153
    e. Cycle -entry 175
    f. Cycle -entry 176

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

- **Embryo-Fetal Toxicity:** Based on findings from animal reproduction studies, MIMRYLO may cause fetal harm when administered to a pregnant woman. Advise patients to stop taking MIMRYLO if they become pregnant.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

Patient Education

The health system determines what patient education should be added to the EHR and included as part of the patient discharge process. The request to add custom patient education resources typically includes the following details.

Information	Details to Include
Name or Title of Resource	For example, Takeda Oncology Here2Assist
Contents	Links to the resources to include
Method(s) of Delivery to the Patient	• As a handout to print and hand to the patient • Available to send via Oracle® Health Patient Portal
Define the Audience for the Document	Patients interested in learning more about MIMRYLO™ (rusfertide) treatment
Methods of Use	• Patient-facing to use in discussion with healthcare provider • Added to Visit Summary • Send to patient via Oracle Health Patient Portal
Specify How Users Will Access the Document	• Via a reference link • Via Patient Education component on the workflow mPage • Patient Education button on the toolbar
Optional Hyperlink (Enabling Patient Access to External Information)	Takeda Oncology Here2Assist here2assist.com or through www.MIMRYLO.com for the digital enrollment platform

IMPORTANT SAFETY INFORMATION (cont.)

ADVERSE REACTIONS

The most common (>15%) adverse reactions were injection site reactions (56%) and anemia (16%).

USE IN SPECIFIC POPULATIONS

- **Lactation:** Because of the potential for serious adverse reactions in the breastfed child, including impaired iron absorption, advise patients not to breastfeed during treatment with MIMRYLO and for 30 days after the final treatment.
- **Females and Males of Reproductive Potential**
  - **Pregnancy Testing:** Prior to initiating MIMRYLO, pregnancy testing is recommended for females of reproductive potential.
  - **Contraception:** Advise female patients of reproductive potential to use effective contraception during treatment with MIMRYLO and for at least 30 days after the final dose of MIMRYLO.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

Patient Education (cont.)

Adding Patient Resources to Custom Library

Providers can opt to personalize patient education for their patient population, when appropriate.

1. Navigate to **Patient Education** on the Toolbar.
2. In the **Patient Education** feature, **Instructions** tab, search for an appropriate education topic; double-click to select the document, and display it on the screen.
3. Once the selected document displays, edit, delete, or add information appropriate for patient focus.
4. Right-click on the title of the document to display options for custom designations.



Example of the context menu for instructions

5. Rename the customized Instructions document, MIMRYLO™ (rusfertide) Instructions then select **OK**.



Example of the Save Custom Instructions dialog box

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **New or Worsening Thrombocytosis:** MIMRYLO may increase platelet counts in patients with PV. Platelet counts generally plateaued on treatment by Week 8. After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated. Platelet elevations associated with MIMRYLO may require cytoreductive therapy initiation, modification, or MIMRYLO dose modifications or discontinuation.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Patient Education (cont.)

6. Patient education resources can be created from a blank (Custom) template, rather than editing an existing document, using the same process.



Example of selecting a blank template to build custom patient education

Adding Patient Education to the Care Summary

Any Patient Resource information added to or selected from the Patient Education section of the visit documentation will be displayed in the Care Summary. There must be an active diagnosis on the encounter prior to choosing Patient Education for Suggested Education to display.

1. After adding a diagnosis, select **Patient Education** in the **Workflow** menu.
2. The **Patient Education** window opens to display **Suggested** education materials based on the diagnosis.
3. To add additional resources, search for additional topics using **More Options….**
4. Any **Patient Education** already added for the visit will display under the **Added Education** heading. Educational materials can be saved as a **Favorite** using the star icon.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

- **Injection-Site Reactions:** Injection site reactions (including Grade 3 reactions) have been reported in patients treated with MIMRYLO. The most common injection site reactions reported were erythema, pruritus, pain, and swelling. Use ice, topical corticosteroid creams, antihistamines or analgesics, as needed, to treat injection site pain and swelling.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Patient Education (cont.)



Example of adding Patient Education to the Care Summary

5. Use the **Modify** button to customize education with additional text.
6. Patient Education materials will be included with the Care Summary, filed in the patient chart under Patient Instruction Sheets, and sent to the Patient Portal, if appropriate.

   Note: *The Patient Education link on the Toolbar enables access to Patient Education outside of the Ambulatory Workflow menu. Information can be printed independently of the Care Summary using the print option under Preview.*

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

- **Embryo-Fetal Toxicity:** Based on findings from animal reproduction studies, MIMRYLO may cause fetal harm when administered to a pregnant woman. Advise patients to stop taking MIMRYLO if they become pregnant.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

EHR Worksheets

Report Criteria

This criteria supports identifying patients with PV on MIMRYLO™ (rusfertide) therapy who may require dose adjustment.

Inclusion Criteria

Category	✔	Values
Patient Status	☐	Alive
Patient Population	☐	Only my patients
	☐	Seen in my department
	☐	All patients who meet the criteria
	☐	Other
Patient Gender	☐	Female
	☐	Male
	☐	Not specified
Race/Ethnicity	☐	White
	☐	Black or African American
	☐	American Indian or Alaska Native
	☐	Asian
	☐	Native Hawaiian or other Pacific Islander
	☐	Not specified
Age	☐	Custom range -

IMPORTANT SAFETY INFORMATION (cont.)

ADVERSE REACTIONS

The most common (>15%) adverse reactions were injection site reactions (56%) and anemia (16%).

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

EHR Worksheets (cont.)

Inclusion Criteria (cont.)

Category	✔	Description	Code Set	Code	Result
Diagnosis	☐	Polycythemia vera	ICD-10	D45	
Lab Result	☐	Hematocrit	CPT	85014, 85025	≥ 45%
Medication	☐	MIMRYLO™ (rusfertide)			
	☐	BESREMi® (ropeginterferon-alfa-2b-njft)			
	☐	Jakafi® (ruxolitinib)			
	☐	Jakafi XR™ (ruxolitinib)			
	☐	Hydrea (hydroxyurea)			
Procedure	☐	Therapeutic phlebotomy	CPT	99195	
	Timeframe for capturing and/or Value (e.g., within the last 6 months is [m-6])			Lookback period (starting today):	

Exclusion Criteria

Category	✔	Description	Code Set	Code	Status
	☐	Other			
	Timeframe for capturing and/or Value (e.g., within the last 6 months is [m-6])			Lookback period (starting today):	

IMPORTANT SAFETY INFORMATION (cont.)

USE IN SPECIFIC POPULATIONS

- **Lactation:** Because of the potential for serious adverse reactions in the breastfed child, including impaired iron absorption, advise patients not to breastfeed during treatment with MIMRYLO and for 30 days after the final treatment.
- **Females and Males of Reproductive Potential**
  - **Pregnancy Testing:** Prior to initiating MIMRYLO, pregnancy testing is recommended for females of reproductive potential.
  - **Contraception:** Advise female patients of reproductive potential to use effective contraception during treatment with MIMRYLO and for at least 30 days after the final dose of MIMRYLO.

EHR Worksheets (cont.)

Report Output

Report Output	✔	Description	Code Set	Code
Patient Demographics	☐	Name		
	☐	MRN		
	☐	DOB		
Diagnosis	☐			
Medication	☐			
Procedures	☐	Therapeutic phlebotomy date		
Lab Result	☐	Hematocrit and date of last result		

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **New or Worsening Thrombocytosis:** MIMRYLO may increase platelet counts in patients with PV. Platelet counts generally plateaued on treatment by Week 8. After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated. Platelet elevations associated with MIMRYLO may require cytoreductive therapy initiation, modification, or MIMRYLO dose modifications or discontinuation.
- **Injection-Site Reactions:** Injection site reactions (including Grade 3 reactions) have been reported in patients treated with MIMRYLO. The most common injection site reactions reported were erythema, pruritus, pain, and swelling. Use ice, topical corticosteroid creams, antihistamines or analgesics, as needed, to treat injection site pain and swelling.
- **Embryo-Fetal Toxicity:** Based on findings from animal reproduction studies, MIMRYLO may cause fetal harm when administered to a pregnant woman. Advise patients to stop taking MIMRYLO if they become pregnant.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

EHR Worksheets (cont.)

Reminder Criteria

Category	✔	Values
Discern Alert Name Patients with polycythemia vera prescribed MIMRYLO™ (rusfertide) with HCT ≥45%	☐	
Message to Include in Discern Alert Patient has a recent HCT ≥45% and is on MIMRYLO. Review clinical data for potential dose adjustment.	☐	
Clinical Data to Display on Discern Alert	☐	Polycythemia Vera D45
	☐	
Reminder Trigger Criteria	☐	Opening of patient chart
	☐	
Frequency of Reminder	☐	Once per encounter
	☐	Once per encounter per user
	☐	Multiple times per event within the encounter
	☐	

IMPORTANT SAFETY INFORMATION (cont.)

ADVERSE REACTIONS

The most common (>15%) adverse reactions were injection site reactions (56%) and anemia (16%).

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Mimrylo™ rusfertide for injection

EHR Worksheets (cont.)

Reminder Criteria (cont.)

Category	✔	Values	
Display Restrictions	☐	Care team member	
	☐	Physician	
	☐	Department	
	☐	Other	
Clinical Actions to Take Based on the Reminder	☐	Open PV SmartSet	Order Set #
	☐	Order MIMRYLO™ (rusfertide)	
	☐	View Hematocrit Result	
	☐	Other	
Acknowledge Reason(s)	☐	Patient refused	Lockout Period
	☐	Continue to monitor	Lockout Period
	☐	Other	Lockout Period
	☐		Lockout Period

IMPORTANT SAFETY INFORMATION (cont.)

USE IN SPECIFIC POPULATIONS

- **Lactation:** Because of the potential for serious adverse reactions in the breastfed child, including impaired iron absorption, advise patients not to breastfeed during treatment with MIMRYLO and for 30 days after the final treatment.
- **Females and Males of Reproductive Potential**
  - **Pregnancy Testing:** Prior to initiating MIMRYLO, pregnancy testing is recommended for females of reproductive potential.
  - **Contraception:** Advise female patients of reproductive potential to use effective contraception during treatment with MIMRYLO and for at least 30 days after the final dose of MIMRYLO.

Please see additional Important Safety Information throughout and on page 43. Please see MIMRYLO (rusfertide) full Prescribing Information.

Important Safety Information and Indication

INDICATION

MIMRYLO is indicated for the treatment of erythrocytosis in adults with polycythemia vera (PV).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **New or Worsening Thrombocytosis:** MIMRYLO may increase platelet counts in patients with PV. Platelet counts generally plateaued on treatment by Week 8. After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated. Platelet elevations associated with MIMRYLO may require cytoreductive therapy initiation, modification, or MIMRYLO dose modifications or discontinuation.
- **Injection-Site Reactions:** Injection site reactions (including Grade 3 reactions) have been reported in patients treated with MIMRYLO. The most common injection site reactions reported were erythema, pruritus, pain, and swelling. Use ice, topical corticosteroid creams, antihistamines or analgesics, as needed, to treat injection site pain and swelling.
- **Embryo-Fetal Toxicity:** Based on findings from animal reproduction studies, MIMRYLO may cause fetal harm when administered to a pregnant woman. Advise patients to stop taking MIMRYLO if they become pregnant.

ADVERSE REACTIONS

The most common (>15%) adverse reactions were injection site reactions (56%) and anemia (16%).

USE IN SPECIFIC POPULATIONS

- **Lactation:** Because of the potential for serious adverse reactions in the breastfed child, including impaired iron absorption, advise patients not to breastfeed during treatment with MIMRYLO and for 30 days after the final treatment.
- **Females and Males of Reproductive Potential**
    - **Pregnancy Testing:** Prior to initiating MIMRYLO, pregnancy testing is recommended for females of reproductive potential.
    - **Contraception:** Advise female patients of reproductive potential to use effective contraception during treatment with MIMRYLO and for at least 30 days after the final dose of MIMRYLO.

To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-844-662-8532 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see MIMRYLO (rusfertide) full Prescribing Information.

References: 1. Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. *Blood.* 2017;129(6):667-679. doi:10.1182/blood-2016-10-695940. **2.** Verstovsek S, Pemmaraju N, Reaven NL, et al. Real-world treatments and thrombotic events in polycythemia vera patients in the USA. *Ann Hematol.* 2023;102(3):571-581. doi:10.1007/s00277-023-05089-6. **3.** Verstovsek S, Pemmaraju N, Reaven NL, et al. Real-world treatments and thrombotic events in polycythemia vera patients in the USA. Electronic Supplemental Material. *Ann Hematol.* 2023;102(3):571-581. doi:10.1007/s00277-023-05089-6. **4.** Poullet A, Busque L, Sirhan S, et al. Symptom burden in myeloproliferative neoplasms: clinical correlates, dynamics, and survival impact—a study of 784 patients from the Quebec MPN research group. *Blood Cancer J.* 2025;15(1):51. doi:10.1038/s41408-025-01234-8. **5.** Kuykendall AT, Fine JT, Kremyanskaya M. Contemporary challenges in polycythemia vera management from the perspective of patients and physicians. *Clin Lymphoma Myeloma Leuk.* 2024;24(8):512-522. doi:10.1016/j.clml.2024.04.003. **6.** Randrianarisoa RMF, Ramanandafy H, Mania A, et al. Prevalence and diagnostic performance of iron deficiency in polycythemia. *Hematology.* 2023;28(1):2204621. doi:10.1080/16078454.2023.2204621. **7.** Handa S, Ginzburg Y, Hoffman R, et al. Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis. *Curr Opin Hematol.* 2023;30(2):45-52. doi:10.1097/MOH.0000000000000747. **8.** Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. *N Engl J Med.* 2013;368(1):22-33. doi:10.1056/NEJMoa1208500. **9.** Poullet A, Busque L, Sirhan S, et al. Symptom burden in myeloproliferative neoplasms: clinical correlates, dynamics, and survival impact—a study of 784 patients from the Quebec MPN Research Group. Supplemental Figure 1. *Blood Cancer J.* 2025;15:51. doi:10.1038/s41408-025-01234-8. **10.** Griesshammer M, Kiladjian JJ, Besses C. Thromboembolic events in polycythemia vera. *Ann Hematol.* 2019;98(5):1071-1082. doi:10.1007/s00277-019-03625-x. **11.** Mesa RA, Miller CB, Thyne M, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: findings from the MPN Landmark survey. *Cancer.* 2017;123(3):449-458. doi:10.1002/cncr.30325. **12.** Ginzburg YZ, Feola M, Zimran E, et al. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. *Leukemia.* 2018;32(10):2105-2116. doi:10.1038/s41375-018-0207-9. **13.** Bennett C, Jackson VE, Pettikiriarachchi A, et al. Iron homeostasis governs erythroid phenotype in polycythemia vera. *Blood.* 2023;141(26):3199-3214. doi:10.1182/blood.2022016779. **14.** Cleveland Clinic. Iron-Deficiency Anemia. Revised December, 2024. Accessed March, 2026. Available at: https://my.clevelandclinic.org/health/diseases/22824-iron-deficiency-anemia. **15.** Visweshwar N, Fletcher B, Jaglal M, et al. Impact of phlebotomy on quality of life in low-risk polycythemia vera. *J Clin Med.* 2024;13(16):4952. doi:10.3390/jcm13164952.

500 Kendall Street, Cambridge, MA 02142.
1-877-TAKEDA-7 (1-877-825-3327).

Takeda

Mimrylo™ rusfertide for injection